Research Analysts Offer Predictions for APVO Q1 Earnings

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Investment analysts at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Aptevo Therapeutics in a note issued to investors on Thursday, November 7th. Roth Capital analyst J. Aschoff expects that the biotechnology company will earn ($0.28) per share for the quarter. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($2.97) per share. Roth Capital also issued estimates for Aptevo Therapeutics’ Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.25) EPS and Q4 2025 earnings at ($0.25) EPS.

Several other research analysts have also recently weighed in on the company. StockNews.com assumed coverage on Aptevo Therapeutics in a research note on Thursday, November 7th. They set a “sell” rating for the company. Roth Mkm reduced their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

Aptevo Therapeutics Price Performance

NASDAQ:APVO opened at $0.27 on Monday. The business has a fifty day moving average of $0.24 and a 200-day moving average of $0.45. Aptevo Therapeutics has a 1 year low of $0.14 and a 1 year high of $10.80.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics as of its most recent filing with the SEC. Institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.